Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis

Haematologica

Volumn 96, Issue 3, 2011, Pages 459-463

  Wilson, Todd M ^a   Maric, Irina ^b   Simakova, Olga ^b   Bai, Yun ^a   Chan, Eunice Ching ^a   Olivares, Nicolas ^b   Carter, Melody ^a   Maric, Dragan ^c   Robyn, Jamie ^d   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CLINICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Activating mutations; NRAS KIT; Systemic mastocytosis

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; GUANOSINE TRIPHOSPHATASE; H RAS PROTEIN; K RAS PROTEIN; PROTEIN N RAS; RNA; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CELL EXPANSION; CELL MATURATION; CELL SURVIVAL; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAST CELL; MISSENSE MUTATION; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; PATHOGENESIS; PHENOTYPIC VARIATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; SOMATIC MUTATION; SYSTEMIC MASTOCYTOSIS;

AGED; ANTIBODIES; ANTIGENS, CD34; BONE MARROW; CLONE CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 79952336888     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031690     Document Type: Article

References (24)

1. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci. USA. 1995;92(23):10560-4.
2. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366-72.
3. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood. 2006;108(7):2349-57.
4. Wiesner SM, Jones JM, Hasz DE, Largaespada DA. Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. Blood. 2005;106(3): 1054-62.
5. Horny H-P, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2008.
6. Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007;120(3):680-7.
7. Kulka M, Fukuishi N, Metcalfe DD. Human mast cells synthesize and release angiogenin, a member of the ribonuclease A (RNase A) superfamily. J Leukoc Biol. 2009;86(5):1217-26.
8. Sotlar K, Bache A, Stellmacher F, Bultmann B, Valent P, Horny HP. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn. 2008;10(1): 58-66.
9. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23(5):900-4.
10. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22(5):915-31.
11. Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, et al. Acquisition of FLT3 or Nras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004;18(3):466-75.
12. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RASBRAF signal transduction pathway in therapy- related myelodysplasia and acute myeloid leukemia. Leukemia. 2005;19(12): 2232-40.
13. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 2000;28(2):140-7.
14. Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. Faseb J. 2008;22(8): 2605-22.
15. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2(7):502-13.
16. Shih LY, Liang DC, Huang CF, Chang YT, Lai CL, Lin TH, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2008;22(2):303-7.
17. Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, et al. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. Eur J Haematol. 2009;83(2):90-8.
18. Shefler I, Mekori YA, Mor A. Stimulation of human mast cells by activated T cells leads to N-Ras activation through Ras guanine nucleotide releasing protein 1. J Allergy Clin Immunol. 2008;122(6):1222-5.
19. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, et al. Phase II study of dasatinib in Philadelphia chromosome- negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12): 3906-15.
20. Gotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C, et al. The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a Phase II trial. Blood. 2007;110: 1035a.
21. Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008;38(11):869-73.
22. Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, et al. Chemotherapy and dasatinib induce longterm hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res. 2009;33(5):735-41.
23. Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4603-9.
24. Illmer T, Thiede C, Fredersdorf A, Stadler S, Neubauer A, Ehninger G, et al. Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res. 2005;11(9):3217-24.